Almirall S.A. - Asset Resilience Ratio
Almirall S.A. (ALM) has an Asset Resilience Ratio of 0.01% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ALM strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2024)
This chart shows how Almirall S.A.'s Asset Resilience Ratio has changed over time. See ALM equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Almirall S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Almirall S.A. (ALM) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €282.00K | 0.01% |
| Total Liquid Assets | €282.00K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Almirall S.A. maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Almirall S.A. Industry Peers by Asset Resilience Ratio
Compare Almirall S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Almirall S.A. (2003–2024)
The table below shows the annual Asset Resilience Ratio data for Almirall S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.01% | €201.00K ≈ $234.99K |
€2.40 Billion ≈ $2.80 Billion |
+0.00pp |
| 2023-12-31 | 0.01% | €136.00K ≈ $159.00K |
€2.37 Billion ≈ $2.78 Billion |
-11.58pp |
| 2022-12-31 | 11.59% | €248.82 Million ≈ $290.90 Million |
€2.15 Billion ≈ $2.51 Billion |
+1.90pp |
| 2021-12-31 | 9.68% | €207.39 Million ≈ $242.46 Million |
€2.14 Billion ≈ $2.50 Billion |
+2.45pp |
| 2020-12-31 | 7.23% | €165.67 Million ≈ $193.68 Million |
€2.29 Billion ≈ $2.68 Billion |
+7.23pp |
| 2019-12-31 | 0.00% | €82.00K ≈ $95.87K |
€2.44 Billion ≈ $2.85 Billion |
-0.04pp |
| 2018-12-31 | 0.05% | €1.08 Million ≈ $1.26 Million |
€2.39 Billion ≈ $2.79 Billion |
-3.11pp |
| 2017-12-31 | 3.16% | €68.68 Million ≈ $80.30 Million |
€2.18 Billion ≈ $2.54 Billion |
-4.55pp |
| 2016-12-31 | 7.71% | €217.21 Million ≈ $253.94 Million |
€2.82 Billion ≈ $3.30 Billion |
-2.96pp |
| 2015-12-31 | 10.66% | €270.04 Million ≈ $315.71 Million |
€2.53 Billion ≈ $2.96 Billion |
-7.31pp |
| 2014-12-31 | 17.97% | €456.51 Million ≈ $533.70 Million |
€2.54 Billion ≈ $2.97 Billion |
+17.50pp |
| 2013-12-31 | 0.47% | €8.36 Million ≈ $9.77 Million |
€1.77 Billion ≈ $2.07 Billion |
-0.76pp |
| 2012-12-31 | 1.23% | €16.70 Million ≈ $19.52 Million |
€1.36 Billion ≈ $1.59 Billion |
-11.83pp |
| 2011-12-31 | 13.06% | €190.21 Million ≈ $222.37 Million |
€1.46 Billion ≈ $1.70 Billion |
-3.23pp |
| 2010-12-31 | 16.28% | €250.25 Million ≈ $292.56 Million |
€1.54 Billion ≈ $1.80 Billion |
+1.44pp |
| 2009-12-31 | 14.84% | €220.15 Million ≈ $257.38 Million |
€1.48 Billion ≈ $1.73 Billion |
+4.56pp |
| 2008-12-31 | 10.29% | €143.68 Million ≈ $167.98 Million |
€1.40 Billion ≈ $1.63 Billion |
+0.21pp |
| 2007-12-31 | 10.08% | €145.05 Million ≈ $169.58 Million |
€1.44 Billion ≈ $1.68 Billion |
-25.68pp |
| 2006-12-31 | 35.76% | €398.39 Million ≈ $465.76 Million |
€1.11 Billion ≈ $1.30 Billion |
-2.14pp |
| 2005-12-31 | 37.90% | €455.70 Million ≈ $532.76 Million |
€1.20 Billion ≈ $1.41 Billion |
+4.50pp |
| 2004-12-31 | 33.40% | €283.61 Million ≈ $331.56 Million |
€849.03 Million ≈ $992.61 Million |
+8.17pp |
| 2003-12-31 | 25.23% | €201.16 Million ≈ $235.18 Million |
€797.27 Million ≈ $932.09 Million |
-- |
About Almirall S.A.
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfecti… Read more